White House Withdraws CDC Director Nominee Dave Weldon
The White House withdrew Dr. Dave Weldon's nomination as CDC director just before his Senate hearing. His vaccine safety ...
Sierra Sun Times18h
NIH Reports Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
Technology Networks1d
Tecovirimat Is Safe but Ineffective as a Treatment for Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
News-Medical.Net1d
Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial
NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...
Mirage News1d
Tecovirimat Safe But Ineffective for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
NIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
ACTG Presents Data from Mpox Study STOMP at CROI
ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...